Robert E. Burrier

2.7k total citations · 1 hit paper
37 papers, 2.0k citations indexed

About

Robert E. Burrier is a scholar working on Molecular Biology, Surgery and Cancer Research. According to data from OpenAlex, Robert E. Burrier has authored 37 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Surgery and 9 papers in Cancer Research. Recurrent topics in Robert E. Burrier's work include Cholesterol and Lipid Metabolism (10 papers), Cancer, Lipids, and Metabolism (5 papers) and Autism Spectrum Disorder Research (5 papers). Robert E. Burrier is often cited by papers focused on Cholesterol and Lipid Metabolism (10 papers), Cancer, Lipids, and Metabolism (5 papers) and Autism Spectrum Disorder Research (5 papers). Robert E. Burrier collaborates with scholars based in United States, United Kingdom and Switzerland. Robert E. Burrier's co-authors include Benjamin Clémençon, Matthias A. Hediger, Elspeth A. Bruford, Harry R. Davis, John W. Clader, Duane A. Burnett, Mary Ann Caplen, Elizabeth L.R. Donley, Peter Brecher and Alan M. Smith and has published in prestigious journals such as Journal of Biological Chemistry, Nature Biotechnology and PLoS ONE.

In The Last Decade

Robert E. Burrier

37 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The ABCs of membrane transporters in health and disease (SLC series): Introduction

2013 435 citations Matthias A. Hediger, Benjamin Clémençon et al. Molecular Aspects of Medicine profile →

Peers

Countries citing papers authored by Robert E. Burrier

Since Specialization

Citations

This map shows the geographic impact of Robert E. Burrier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Burrier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Burrier more than expected).

Fields of papers citing papers by Robert E. Burrier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Burrier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Burrier. The network helps show where Robert E. Burrier may publish in the future.

Co-authorship network of co-authors of Robert E. Burrier

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Burrier. A scholar is included among the top collaborators of Robert E. Burrier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Burrier. Robert E. Burrier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Metabolomic biomarkers in autism: identification of complex dysregulations of cellular bioenergetics 2023 ·Frontiers in Psychiatry ·Alan M. Smith, Elizabeth L.R. Donley, Denise M. Ney, David G. Amaral, Robert E. Burrier, Marvin R. Natowicz	10
2	microRNAs signatures as potential biomarkers of structural cardiotoxicity in human-induced pluripotent stem-cell derived cardiomyocytes 2022 ·Archives of Toxicology ·Vitalina Gryshkova, (unknown), Jessica Palmer, Robert E. Burrier, Annie Delaunois, Elizabeth L.R. Donley, Jean‐Pierre Valentin	11
3	A Metabolomics Approach to Screening for Autism Risk in the Children's Autism Metabolome Project 2020 ·Autism Research ·Alan M. Smith, Marvin R. Natowicz, Daniel Braas, (unknown), Denise M. Ney, Elizabeth L.R. Donley, Robert E. Burrier, David G. Amaral	41
4	Amino Acid Dysregulation Metabotypes: Potential Biomarkers for Diagnosis and Individualized Treatment for Subtypes of Autism Spectrum Disorder 2018 ·Biological Psychiatry ·Alan M. Smith, Joseph J. King, Paul R. West, (unknown), Elizabeth L.R. Donley, Robert E. Burrier, David G. Amaral	98
5	Prospective validation of molecular subtype diagnostics for autism spectrum and neurodevelopmental disorders (P3.321) 2018 ·Neurology ·Elizabeth L.R. Donley, Robert E. Burrier, Joseph J. King, Alan M. Smith, Paul R. West, (unknown), (unknown), (unknown), Brandon Smart, David G. Amaral	1
6	A human induced pluripotent stem cell-based in vitro assay predicts developmental toxicity through a retinoic acid receptor-mediated pathway for a series of related retinoid analogues 2017 ·Reproductive Toxicology ·Jessica Palmer, Alan M. Smith, Laura A. Egnash, (unknown), Elizabeth L.R. Donley, (unknown), Robert E. Burrier	26
7	The ABCs of membrane transporters in health and disease (SLC series): Introduction breakdown → 2013 ·Molecular Aspects of Medicine ·Matthias A. Hediger, Benjamin Clémençon, Robert E. Burrier, Elspeth A. Bruford	435
8	The sodium-dependent ascorbic acid transporter family SLC23 2013 ·Molecular Aspects of Medicine ·Marc Bürzle, Yoshiro Suzuki, Daniel Ackermann, Hiroki Miyazaki, Nobuyo Maeda, Benjamin Clémençon, Robert E. Burrier, Matthias A. Hediger	125
9	Toxin Binding of Tolevamer, a Polyanionic Drug that Protects against Antibiotic-Associated Diarrhea 2004 ·Biophysical Journal ·William H. Braunlin, Qiuwei Xu, (unknown), Richard Fitzpatrick, Jeffrey D. Klinger, Robert E. Burrier, Caroline B. Kurtz	38
10	The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs 2001 ·Metabolism ·Harry R. Davis, (unknown), Kevin B. Alton, Robert E. Burrier, Robert W. Watkins	72
11	GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists 1998 ·European Journal of Pharmacology ·Eric M. Parker, (unknown), Ambikaipakan Balasubramaniam, Robert E. Burrier, M. Guzzi, (unknown), Gitali Mukhopadhyay, (unknown), Tao Zhang, (unknown), Ling Xia, Deborra Mullins, Brian Salisbury	98
12	Genomic organization and functional characterization of the mouse GalR1 galanin receptor 1997 ·FEBS Letters ·Suke Wang, (unknown), (unknown), Anthony Clemmons, Robert E. Burrier, M. Guzzi, Catherine D. Strader, Eric M. Parker, Marvin Bayne	62
13	ChemInform Abstract: Inhibitors of Acyl CoA: Cholesterol Acyltransferase (ACAT). 1996 ·ChemInform ·Wayne Vaccaro, (unknown), Johannes Berger, Robert E. Burrier, (unknown), Harry R. Davis, Martin S. Domalski, (unknown), Brian Salisbury, Rosy Sher	4
14	Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups on in Vitro and in Vivo Activity 1995 ·Journal of Medicinal Chemistry ·John W. Clader, Joel G. Berger, Robert E. Burrier, Harry R. Davis, Martin S. Domalski, Sundeep Dugar, Timothy P. Kogan, Brian Salisbury, Wayne Vaccaro	22
15	Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461 1995 ·Atherosclerosis ·Brian Salisbury, Harry R. Davis, Robert E. Burrier, Duane A. Burnett, (unknown), Mary Ann Caplen, Anthony Clemmons, Douglas S. Compton, Lizbeth Hoos, (unknown), Robin Schnitzer‐Polokoff, (unknown), Blair Weig, (unknown), John W. Clader, Edmund J. Sybertz	94
16	Amides of piperidine, morpholine and piperazine substituted 1-phenylethylamines: Inhibitors of acylCoA:cholesterol acyltransferase (ACAT) activity in vitro and in vivo 1995 ·Bioorganic & Medicinal Chemistry ·Sundeep Dugar, Harry R. Davis, Robert E. Burrier, Brian Salisbury	2
17	The effect of acyl CoA: cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine. 1995 ·Journal of Pharmacology and Experimental Therapeutics ·Robert E. Burrier, (unknown), (unknown), Lizbeth Hoos, (unknown), Harry R. Davis	21
18	Demonstration of a direct effect on hepatic acyl CoA:cholesterol acyl transferase (ACAT) activity by an orally administered enzyme inhibitor in the hamster 1994 ·Biochemical Pharmacology ·Robert E. Burrier, (unknown), (unknown), Lizbeth Hoos, (unknown), Harry R. Davis	23
19	2-Azetidinones as Inhibitors of Cholesterol Absorption 1994 ·Journal of Medicinal Chemistry ·Duane A. Burnett, Mary Ann Caplen, Harry R. Davis, Robert E. Burrier, John W. Clader	182
20	Effect of surface composition on triolein hydrolysis in phospholipid vesicles and microemulsions by a purified acid lipase 1984 ·Biochemistry ·Robert E. Burrier, Peter Brecher	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact